ReviewCurrent oncology (Toronto, Ont.)2020
Biomarkers of immune checkpoint inhibitor efficacy in cancer.
Review in Current oncology (Toronto, Ont.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 22 citations in OpenAlex.
- Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions.Nature reviews. Clinical oncology · 2025Review
- Article
- Self-assembling peptides as immunomodulatory biomaterials.Frontiers in bioengineering and biotechnology · 2023Review
- Circadian lifestyle determinants of immune checkpoint inhibitor efficacy.Frontiers in oncology · 2023Review
- SAAL1, a novel oncogene, is associated with prognosis and immunotherapy in multiple types of cancer.Aging · 2022Article
- MDIG, a 2‑oxoglutarate‑dependent oxygenase, acts as an oncogene and predicts the prognosis of multiple types of cancer.International journal of oncology · 2022Article
- Analysis of PD-1, PD-L1, and T-cell infiltration in angiosarcoma pathogenetic subgroups.Immunologic research · 2022Article
- Advancements of Common Gamma-Chain Family Cytokines in Cancer Immunotherapy.Immune network · 2022Review
- PD-L1 Expression Is Significantly Associated with Tumor Mutation Burden and Microsatellite Instability Score.Cancers · 2021Article
- Precision medicine: Uses and challenges.Medical journal, Armed Forces India · 2021Review
- Response Prediction in Immune Checkpoint Inhibitor Immunotherapy for Advanced Hepatocellular Carcinoma.Cancers · 2021Article
- Serum Levels of Soluble Urokinase Plasminogen Activator Receptor Predict Tumor Response and Outcome to Immune Checkpoint Inhibitor Therapy.Frontiers in oncology · 2021Article
- Lymph Node Immune Profiles as Predictive Biomarkers for Immune Checkpoint Inhibitor Response.Frontiers in molecular biosciences · 2021Review
- The Predictive Role of Immune Related Subgroup Classification in Immune Checkpoint Blockade Therapy for Lung Adenocarcinoma.Frontiers in genetics · 2021Article
- Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer.OncoTargets and therapy · 2021Review
- Immunotherapy Benefit in a Patient With Non-Small Cell Lung Cancer and a Rare BRAF Mutation.Cureus · 2020Article
- Activating the Antitumor Immune Response in Non-Hodgkin Lymphoma Using Immune Checkpoint Inhibitors.Journal of immunology research · 2020Review
- Prognostic and Immunological Role of FAT Family Genes in Non-Small Cell Lung Cancer.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitor-based therapies that target ctla-4, PD-1, or the PD-1 ligand PD-L1 have received approval in Canada and many parts of the world for the treatment of melanoma, renal cell cancer, urothelial cancer, classical Hodgkin lymphoma, and non-small-cell lung cancer. However only a small proportion of patients derive long-term clinical benefit. Here, we describe the biomarkers associated with the complex relationship between tumour-related immune stimulus, T cell-mediated immune response, and immune modulation of the microenvironment that can help to predict improved patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.